A study published in Frontiers in Pharmacology has found that the pharmacokinetic characteristics and immunogenicity of Livzon Mabpharm’s LZM008 were similar to Genentech’s ACTEMRA®. The safety profiles of LZM008 were similar in two groups with mild–moderate adverse effects. The study was a randomised, double-blinded, single-dose, parallel-group phase I clinical trial conducted in Huashan Hospital and Wuxi People’s Hospital in China. The incidence of treatment emergent adverse events was comparable in LZM008 and ACTEMRA® groups (98% versus 100%). The study was funded by the Livzon Mabpharm Inc. and the Ministry of Science and Technology of China.
In February 2023, Fresenius Kabi demonstrated bioequivalence for its tocilizumab biosimilar.